Cancer

M2GEN – Accelerating Cancer Research

M2GEN - Accelerating Cancer Research

Dr. Todd Johnson, M.D. is the Chief Growth Officer at M2GEN, an oncology-focused health informatics solutions company with the mission to help patients get access to the best treatments by leveraging clinical and molecular data to accelerate the discovery, development, and delivery of tailored and more personalized therapies. 

Frequently Asked Questions

What is the main topic discussed in this episode of Health Professional Radio?

This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.

How can healthcare professionals benefit from this information?

Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.

Where can I find more information about Cancer?

For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.

Dr. Todd Johnson is Chief Growth Officer for M2GEN. He previously served as Senior Advisor to Clayton, Dubilier & Rice in Healthcare/Real World Data, to which he brought a 20-year track record building and managing high-performing, innovative Life Sciences data and services businesses. His previous experiences include the founding and management of Optum’s Clinical Research Group, co-founding and serving as president and board member at CytoVas, a liquid biopsy company, Noble.MD, an innovative patient data platform sold to WellTrackOne, Abbott Labs/AbbVie’s pharmaceutical pipeline, and MDS / Celerion, a drug development business sold to Bain Capital. Early in his career, Dr. Johnson was a cancer biologist at the Dana-Farber Cancer Institute, and at the Peter Nowell lab at Penn. Dr. Johnson holds a Bachelor of Arts from Penn, an ABA from Oxford, an MD from the Perelman School of Medicine at the University of Pennsylvania, and an MBA from Wharton.

Last updated: October 12, 2022

Medical Disclaimer

The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.